User menu

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Bibliographic reference Cervantes, Francisco ; Vannucchi, Alessandro M. ; Kiladjian, Jean-Jacques ; Al-Ali, Haifa Kathrin ; Sirulnik, Andres ; et. al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.. In: Blood, Vol. 122, no.25, p. 4047-53 (2013)
Permanent URL http://hdl.handle.net/2078.1/141284